New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
04:55 EDTJNJ, JNJ, SYK, SYK, NVDQ, NVDQ, COV, COV, CNMD, CNMD, ISRG, ISRGPiper Jaffray to hold booth tours
Booth Tours at SAGES Annual Meeting will be held in Salt Lake City, Utah on April 2-3.
News For JNJ;SYK;NVDQ;COV;CNMD;ISRG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
January 15, 2015
16:05 EDTJNJDepomed to acquire U.S. rights to NUCYNTA franchise for $1.05B from Jansen
12:10 EDTJNJJohnson & Johnson volatility elevated into Q4 and outlook
Johnson & Johnson January weekly call option implied volatility is at 22, February is at 16, April is at 15; compared to its 26-week average of 15 according to Track Data, suggesting large movement into the expected release of Q4 results on January 20.
11:20 EDTJNJGoldman cuts J&J to sell citing competitive pressures
Subscribe for More Information
10:19 EDTISRGOptions with decreasing implied volatility
Subscribe for More Information
10:00 EDTJNJOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: American Campus (ACC) downgraded to Sell from Neutral at Goldman... Apple (AAPL) downgraded to Neutral from Buy at Mizuho... Archer Daniels (ADM) downgraded to Neutral from Buy at Goldman... Barrick Gold (ABX) downgraded to Underweight from Equal Weight at Barclays... CNOOC (CEO) downgraded to Underperform from Hold at Jefferies... CSC (CSC) downgraded to Underweight from Neutral at JPMorgan... Computer Programs (CPSI) downgraded to Market Perform from Outperform at William Blair... D.R. Horton (DHI) downgraded to Neutral from Buy at UBS... DDR Corp. (DDR) downgraded to Neutral from Overweight at JPMorgan... Dominion Diamond (DDC) downgraded to Equal Weight from Overweight at Barclays... EVERTEC (EVTC) downgraded to Neutral from Overweight at JPMorgan... Education Realty (EDR) downgraded to Sell from Neutral at Goldman... Franco-Nevada (FNV) downgraded to Underweight from Equal Weight at Barclays... General Cable (BGC) downgraded to Neutral from Buy at Longbow... Green Dot (GDOT) downgraded to Neutral from Overweight at JPMorgan... Greif (GEF) downgraded to Neutral from Buy at BofA/Merrill... Grupo Simec (SIM) downgraded to Neutral from Buy at Goldman... Hecla Mining (HL) downgraded to Hold from Buy at BB&T... Host Hotels (HST) downgraded to Hold from Buy at MLV & Co.... Ingredion (INGR) downgraded to Sell from Neutral at Goldman... Insulet (PODD) downgraded to Market Perform from Outperform at Raymond James... Johnson & Johnson (JNJ) downgraded to Sell from Neutral at Goldman... Magna (MGA) downgraded to Hold from Buy at TD Securities... Molson Coors (TAP) downgraded to Neutral from Buy at Goldman... Nuverra Environmental (NES) downgraded at Roth Capital... Omnicom (OMC) downgraded to Hold from Buy at Evercore ISI... PetroChina (PTR) downgraded to Underperform from Hold at Jefferies... Philip Morris (PM) downgraded to Sell from Neutral at Goldman... Precision Castparts (PCP) downgraded to Hold from Buy at KeyBanc... Rio Tinto (RIO) downgraded to Neutral from Outperform at Macquarie... STAG Industrial (STAG) downgraded to Neutral from Overweight at JPMorgan... Silicon Laboratories (SLAB) downgraded to Equal Weight from Overweight at Barclays... Sinopec (SNP) downgraded to Underperform from Hold at Jefferies... Sky (SKYAY) downgraded to Neutral from Outperform at Exane BNP Paribas... Teledyne (TDY) downgraded to Underweight from Hold at KeyBanc... Woodward (WWD) downgraded to Underweight from Hold at KeyBanc... Xilinx (XLNX) downgraded to Equal Weight from Overweight at Barclays.
07:06 EDTJNJJohnson & Johnson downgraded at Goldman
Subscribe for More Information
06:44 EDTJNJJohnson & Johnson downgraded to Sell from Neutral at Goldman
January 14, 2015
10:10 EDTSYKHigh option volume stocks
Subscribe for More Information
09:51 EDTJNJJohnson & Johnson unit says study shows consistent Xarelto safety
Johnson & Johnson unit Janssen announced that a new post-marketing study evaluating the safety of once-daily Xarelto shows, in patients with non-valvular atrial fibrillation, rates and patterns of major bleeding in routine clinical practice are generally consistent with those observed in Phase 3 clinical trials used to approve the medicine for this indication. The fifteen-month results, published today in Clinical Cardiology, represent initial findings from an ongoing, five-year, observational study of patients using Xarelto daily over the course of their lives.
07:07 EDTCNMDCONMED sees FY15 adjusted EPS $1.92-$2.02, consensus $2.02
Sees FY15 revenue $740M-$755M, consensus $746.46M.
07:06 EDTCNMDCONMED reports preliminary FY14 adjusted EPS $1.90-$1.94, consensus $1.93
Reports preliminary FY14 revenue $739M-$741M, consensus $741.06M.
January 13, 2015
17:43 EDTSYKStryker sees FY15 EPS negatively impacted by 20c
Subscribe for More Information
17:40 EDTSYKStryker sees FY14 EPS $4.72-$4.74, consensus $4.75
Sees FY14 revenue $9.7B, consensus $9.69B.
17:39 EDTSYKStryker sees Q4 adjusted EPS $1.43-$1.45, consensus $1.46
Subscribe for More Information
16:00 EDTJNJOptions Update; January 13, 2015
iPath S&P 500 VIX Short-Term Futures up 66c to 34.42. Option volume leaders: AAPL JNJ CELG WFM TSLA TWTR AMZN GILD according to Track Data.
10:00 EDTJNJJanssen Biotech announces license agreement with Vedanta Biosciences
Subscribe for More Information
08:57 EDTNVDQNovadaq shares should be bought on weakness, says JMP Securities
Subscribe for More Information
08:40 EDTISRGIntuitive Surgical reports preliminary Q4 revenue $605M, consensus $587.48M
Intuitive Surgical announced certain unaudited preliminary Q4 financial results. The company expects GAAP revenue for Q4 of approximately $605M, up approximately 5% from $576M for the 4Q13. The company expects non-GAAP revenue for Q4 of approximately $601M, which excludes approximately $4M of revenue associated with da Vinci Xi trade-out offers. The unaudited preliminary results are prior to the completion of our annual independent audit and therefore are subject to adjustment. Preliminary Q4 instruments and accessories revenue on a GAAP basis is expected to increase approximately 5% to approximately $281M from $268M during 4Q13. Preliminary fourth quarter 2014 da Vinci Surgical Systems revenue on a GAAP basis is expected to increase approximately 5% to approximately $214M from $205M during 4Q13. The company placed 137 da Vinci Surgical Systems during Q4, compared with 138 systems during 4Q13. The Preliminary Q4 GAAP service revenue is expected to increase approximately 6% to approximately $110M from $103M during 4Q13.
07:45 EDTJNJFierce Biotech to hold a breakfast meeting
Subscribe for More Information
07:42 EDTNVDQJPMorgan to hold a conference
33rd Annual Healthcare Conference is being held in San Francisco on January 12-15 with webcasted company presentations to begin on January 13 at 10:30 am; not all company presentations may be webcasted. Webcast Link
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use